CCR5 as a Treatment Target in Pulmonary Arterial Hypertension
Amsellem, Valérie × Lipskaia, Larissa Abid, Shariq Poupel, Lucie Houssaini, Amal Quarck, Rozenn Marcos, Elisabeth Mouraret, Nathalie Parpaleix, Aurélien Bobe, Régis Gary-Bobo, Guillaume Saker, Mirna Dubois-Randé, Jean-Luc Gladwin, Mark T Norris, Karen A Delcroix, Marion Combadière, Christophe Adnot, Serge #
Circulation vol:130 issue:11 pages:880-91
Pulmonary arterial hypertension (PH), whether idiopathic or related to underlying diseases such as HIV infection, results from complex vessel remodeling involving both pulmonary artery smooth muscle cell (PA-SMC) proliferation and inflammation. CCR5, a coreceptor for cellular HIV-1 entry expressed on macrophages and vascular cells, may be involved in the pathogenesis of PH. Maraviroc is a new CCR5 antagonist designed to block HIV entry.